kurskvestЧеловек и его здоровьеHumans and their health1998-57461998-5754Kursk State Medical University10.21626/vestnik/2024-1/02KZKCUIkurskvest-1270Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEПерспективные подходы неинвазивной диагностики субклинической кардиоваскулярной токсичности химиотерапииPromising approaches to noninvasive diagnosis of subclinical cardiovascular toxicity of chemotherapyhttps://orcid.org/0000-0001-8317-322XХардиковаЕлена МихайловнаKhardikovaElena M.

канд. мед. наук, доцент, доцент кафедры внутренних болезней № 1, КГМУ, г. Курск

Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Internal Diseases N 1, KSMU, Russian Federation

rx-elena@yandex.ruhttps://orcid.org/0000-0002-9292-3093МещеринаНаталья СергеевнаMeshcherinaNatalia S.

д-р мед. наук, доцент, зав. каф. внутренних болезней № 1, КГМУ

Dr. Sci. (Med.), Associate Professor, Head of the Department of Internal Diseases No. 1, KSMU, Kursk, Russian Federation

n.mescherina@yandex.ruhttps://orcid.org/0000-0003-3273-5418МихайленкоТатьяна СергеевнаMikhailenkoTatiana S.

ассистент каф. внутренних болезней № 1, КГМУ, г. Курск

assistant lecturer at the Department of Internal Diseases No. 1, KSMU, Kursk, Russian Federation

tata_my95@mail.ruhttps://orcid.org/0000-0003-2699-7235ЛеонтьеваТатьяна СергеевнаLeontievaTatiana S.

ассистент каф. внутренних болезней № 1, КГМУ, г. Курск

assistant lecturer at the Department of Internal Diseases No. 1, KSMU, Kursk, Russian Federation

s-tayana@mail.ruКурский государственный медицинский университет (КГМУ)РоссияKursk State Medical University (KSMU)Russian Federation2024290520242711322Copyright © Хардикова Е.М., Мещерина Н.С., Михайленко Т.С., Леонтьева Т.С., 20242024Хардикова Е.М., Мещерина Н.С., Михайленко Т.С., Леонтьева Т.С.Khardikova E.M., Meshcherina N.S., Mikhailenko T.S., Leontieva T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.kursk-vestnik.ru/jour/article/view/1270

Цель - представить данные об имеющихся современных методах диагностики субклинической кардиоваскулярной токсичности химиотерапии. Современные подходы к терапии онкологических заболеваний способствуют развитию стойкой ремиссии, что позволяет добиться увеличения продолжительности и качества жизни. Однако данные положительные эффекты терапии нивелируются развитием многочисленных побочных эффектов, среди которых наиболее значимыми являются сердечно-сосудистые осложнения. Ранняя диагностика кардиоваскулярной токсичности у онкологических больных является «новой» приоритетной задачей для коллаборации онкологов и кардиологов, так как развитие или прогрессирование уже имеющегося сердечно-сосудистого заболевания оказывает значительное влияние на продолжительность и качество жизни онкобольных. Настоящий обзор посвящен современным методам диагностики и мониторинга субклинической кардиоваскулярной токсичности, обусловленной противоопухолевой терапией. Диагностика субклинической кардиотоксичности включает в себя двухмерную и трехмерную эхокардиографию, спекл-трекинг эхокардиографию, магнитно-резонансную томографию, определение диастолической дисфункции. Данные методы визуализации способствуют ранней диагностике кардиоваскулярной токсичности, что позволяет положительно влиять на прогноз и качество жизни у онкологических больных, получающих химиотерапию.

Objective: to present data on available modern methods of diagnosis of subclinical cardiovascular toxicity of chemotherapy. Modern strategies of treatment of cancer allow to stable remission and increase life expectancy of patients, the success of which is balanced by increased mortality of cancer patients due to the development of side effects of chemotherapy, the most prognostically significant of which are cardiovascular complications. Early diagnosis of cardiovascular toxicity in cancer patients is a “new” priority for collaboration of oncologists and cardiologists, as the development or progression of an already existing heart disease has a significant impact on the duration and quality of life of cancer patients. This review, at the current level of development of medical science, presents methods of diagnosis and monitoring of subclinical cardiovascular toxicity against the background of chemotherapy. Use for the diagnosis of subclinical cardiotoxicity such modern methods of visualization as two- and three-dimensional echocardiography, echocardiography with the definition of global longitudinal deformation of the myocardium - spectrum-tracking echocardiography, myocardial work, magnetic resonance tomography, definition of diastolic dysfunction allows to identify manifestations of cardiovascular toxicity in earlier terms, thereby affecting the prognosis and quality of life in cancer patients receiving chemotherapy treatment.

химиотерапиясубклиническая кардиотоксичностькардиоонкологияchemotherapysubclinical cardiotoxicityReferencesWorld Health Organization Cardiovascular diseases (CVDs) Fact Sheet. 2021. [(accessed on 1 Desember 2021)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)World Health Organization Cardiovascular diseases (CVDs) Fact Sheet. 2021. [(accessed on 1 Desember 2021)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)Федеральная служба государственной статистики: [Электронный ресурс] . URL: https://rosstat.gov.ru/folder/13721Federal State Statistics Service: [Electronic resource] (in Russ.). URL: https://rosstat.gov.ru/folder/13721Pahwa R., Jialal I. Atherosclerosis. Treasure Island (FL): StatPearls Publishing [Internet], 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK507799/Pahwa R., Jialal I. Atherosclerosis. Treasure Island (FL): StatPearls Publishing [Internet], 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK507799/Atlas Writing Group; Timmis A., Townsend N., Gale C.P., Torbica A., Lettino M., Petersen S.E., Mossialos E.A., et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur Heart J Qual Care Clin Outcomes. 2020;6(1):7-9. DOI: 10.1093/ehjqcco/qcz065.Atlas Writing Group; Timmis A., Townsend N., Gale C.P., Torbica A., Lettino M., Petersen S.E., Mossialos E.A., et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur Heart J Qual Care Clin Outcomes. 2020;6(1):7-9. DOI: 10.1093/ehjqcco/qcz065.Altena R., Hubbert L., Kiani N.A., Wengström Y., Bergh J., Hedayati E. Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology. 2021;7(1):20. DOI: 10.1186/s40959-021-00105-y.Altena R., Hubbert L., Kiani N.A., Wengström Y., Bergh J., Hedayati E. Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology. 2021;7(1):20. DOI: 10.1186/s40959-021-00105-y.International agency for research on cancer: cancer tomorrow [electronic resource] URL: https://gco.iarc.fr/tomorrow/en/dataviz/isotypeInternational agency for research on cancer: cancer tomorrow [electronic resource] URL: https://gco.iarc.fr/tomorrow/en/dataviz/isotypeRubens-Figueroa J., Cárdenas-Cardós R. Importance of cardio-oncology. How to detect suclinical heart failure. Arch Cardiol Mex. 2021;91(2):229-234. DOI: 10.24875/ACM.19000394.Rubens-Figueroa J., Cárdenas-Cardós R. Importance of cardio-oncology. How to detect suclinical heart failure. Arch Cardiol Mex. 2021;91(2):229-234. DOI: 10.24875/ACM.19000394.Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. DOI: 10.3322/caac.21654.Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. DOI: 10.3322/caac.21654.Shapiro C.L. Cancer Survivorship. N Engl J Med. 2018;379(25):2438-2450. DOI: 10.1056/NEJMra1712502.Shapiro C.L. Cancer Survivorship. N Engl J Med. 2018;379(25):2438-2450. DOI: 10.1056/NEJMra1712502.Мещерина Н.С., Михайленко Т.С., Хардикова Е.М., Сараев И.А., Леонтьева Т.С. Кардиоваскулярная токсичность, индуцированная химиотерапией и таргетными препаратами: механизмы развития, подходы к диагностике и профилактике. Человек и его здоровье. 2021;24(4):24-33. DOI: 10.21626/vestnik/2021-4/04. EDN: SYUPKS.Mescherina N.S., Mikhailenko T.S., Khardikova E.M., Saraev I.A., Leontieva T.S. Cardiovascular toxicity induced by chemotherapy and target drugs: mechanisms, diagnostic and preventive approaches. Humans and their Health. 2021;24(4):24-33 (in Russ.). DOI: 10.21626/vestnik/2021-4/04. EDN: SYUPKS.Liu Y., Tan D., Shi L., Liu X., Zhang Y., Tong C., Song D., Hou M. Blueberry anthocyanins enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS One. 2015;10(7):e0127813. DOI: 10.1371/journal.pone.0127813.Liu Y., Tan D., Shi L., Liu X., Zhang Y., Tong C., Song D., Hou M. Blueberry anthocyanins enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS One. 2015;10(7):e0127813. DOI: 10.1371/journal.pone.0127813.Dent S., Liu P., Brezden-Masley C., Lenihan D. Cancer and Cardiovascular Disease: The Complex Labyrinth. J Oncol. 2015;2015:516450. DOI: 10.1155/2015/516450.Dent S., Liu P., Brezden-Masley C., Lenihan D. Cancer and Cardiovascular Disease: The Complex Labyrinth. J Oncol. 2015;2015:516450. DOI: 10.1155/2015/516450.Anker M.S., Von Haehling S., Landmesser U., Coats A.J., Anker S.D. Cancer and heart failure-more than meets the eye: Common risk factors and co-morbidities. Eur J Heart Fail. 2018;20(10):1382-1384. DOI: 10.1002/ejhf.1252.Anker M.S., Von Haehling S., Landmesser U., Coats A.J., Anker S.D. Cancer and heart failure-more than meets the eye: Common risk factors and co-morbidities. Eur J Heart Fail. 2018;20(10):1382-1384. DOI: 10.1002/ejhf.1252.Hamo C.E., Bloom M.W., Cardinale D., Ky B., Nohria A., Baer L., Skopicki H., Lenihan D.J., et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. DOI: 10.1161/CIRCHEARTFAILURE.115.002843.Hamo C.E., Bloom M.W., Cardinale D., Ky B., Nohria A., Baer L., Skopicki H., Lenihan D.J., et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. DOI: 10.1161/CIRCHEARTFAILURE.115.002843.Мещерина Н.С., Степченко М.А., Леонтьева Т.С., Хардикова Е.М., Михайленко Т.С. Подходы к ранней диагностике и профилактике кардиоваскулярной токсичности, индуцированной таргетными препаратами и ингибиторами контрольных точек иммунитета, в онкогематологии (обзор литературы). Кардиоваскулярная терапия и профилактика. 2023;22(1):3337. DOI: 10.15829/1728-8800-2023-3337. EDN: NFLIGQ.Mescherina N.S., Stepchenko M.A., Leontieva T.S., Khardikova E.M., Mikhailenko T.S. Approaches to early diagnosis and prevention of cardiovascular toxicity induced by targeted drugs and immune checkpoint inhibitors in oncohematology: a literature review. Cardiovascular Therapy and Prevention. 2023;22(1):3337 (in Russ.). DOI: 10.15829/1728-8800-2023-3337. EDN: NFLIGQ.Vincent L., Leedy D., Masri S.C., Cheng R.K. Cardiovascular disease and Cancer: is there increasing overlap? Curr Oncol Rep. 2019;21(6):47. DOI: 10.1007/s11912-019-0796-0.Vincent L., Leedy D., Masri S.C., Cheng R.K. Cardiovascular disease and Cancer: is there increasing overlap? Curr Oncol Rep. 2019;21(6):47. DOI: 10.1007/s11912-019-0796-0.Rafati S., Baneshi M.R., Bahrampour A. Factors Affecting Long-Survival of Patients with Breast Cancer by Non-Mixture and Mixture Cure Models Using the Weibull, Log-logistic and Dagum Distributions: A Bayesian Approach. Asian Pac J Cancer Prev. 2020;21(2):485-490. DOI: 10.31557/APJCP.2020.21.2.485.Rafati S., Baneshi M.R., Bahrampour A. Factors Affecting Long-Survival of Patients with Breast Cancer by Non-Mixture and Mixture Cure Models Using the Weibull, Log-logistic and Dagum Distributions: A Bayesian Approach. Asian Pac J Cancer Prev. 2020;21(2):485-490. DOI: 10.31557/APJCP.2020.21.2.485.Zaha V.G., Hayek S.S., Alexander K.M., Beckie T.M., Hundley W.G., Kondapalli L., Ky B., Leger K.J., et al. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021;144(25):e551-e563. DOI: 10.1161/CIR.0000000000001032.Zaha V.G., Hayek S.S., Alexander K.M., Beckie T.M., Hundley W.G., Kondapalli L., Ky B., Leger K.J., et al. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021;144(25):e551-e563. DOI: 10.1161/CIR.0000000000001032.Hoeger C.W., Hayek S.S. Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer. Cardiol Clin. 2019;37(4):505-523. DOI: 10.1016/j.ccl.2019.07.015.Hoeger C.W., Hayek S.S. Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer. Cardiol Clin. 2019;37(4):505-523. DOI: 10.1016/j.ccl.2019.07.015.Чазова И.Е., Агеев Ф.Т., Аксенова А.В., Виценя М.В., Гиляров М.Ю., Мартынюк Т.В., Панченко Е.П., Полтавская М.Г., и др. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022;(1): 6-79. DOI: 10.38109/2225-1685-2022-1-6-79. EDN: SIVDQT.Chazova I.E., Ageev F.T., Aksenova A.V., Vicenya M.V., Gilyarov M.Yu., Martynyuk T.V., Panchenko E.P., Poltavskaya M.G., Potievskaya V.I., et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian heart journal. 2022;(1):6-79 (in Russ.). DOI: 10.38109/2225-1685-2022-1-6-79. EDN: SIVDQT.Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. DOI: 10.1093/eurheartj/ehac244.Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. DOI: 10.1093/eurheartj/ehac244.Armenian S.H., Lacchetti C., Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(4):270-275. DOI: 10.1200/JOP.2016.018770.Armenian S.H., Lacchetti C., Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(4):270-275. DOI: 10.1200/JOP.2016.018770.Кириченко Ю.Ю., Ильгисонис И.С., Иванова Т.В., Золотухина А.С., Хабарова Н.В., Привалова Е.В., Беленков Ю.Н. Кардиоваскулотоксические проявления противоопухолевой терапии: влияние на ремоделирование миокарда и сосудистого русла. Кардиоваскулярная терапия и профилактика. 2021;20(7):2923. DOI: 10.15829/1728-8800-2021-2923. EDN: HDSBXX.Kirichenko Yu.Yu., Ilgisonis I.S., Ivanova T.V., Zolotukhina A.S., Khabarova N.V., Privalova E.V., Belenkov Yu.N. Cardiovascular toxicity of antitumor therapy: effect on myocardial and vascular remodeling. Cardiovascular Therapy and Prevention. 2021;20(7):2923 (in Russ.). DOI: 10.15829/1728-8800-2021-2923. EDN: HDSBXX.Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-1093. DOI: 10.1093/ehjci/jeu192.Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-1093. DOI: 10.1093/ehjci/jeu192.Кузьмина Т.П., Давыдкин И.Л., Терешина О.В., Данилова О.Е., Шпигель А.С., Бетанели Т.Ш., Наумова К.В., Попельнюк Н.С. Кардиотоксичность и методы ее диагностики у пациентов гематологического профиля (обзор литературы). Сибирский научный медицинский журнал. 2019;39(1):34-42. DOI: 10.15372/SSMJ20190105. EDN: YZAKFN.Kuzmina T.P., Davydkin I.L., Tereshina O.V., Danilova O.E., Shpigel A.S., Betaneli T.S., Naumova K.V., Popelnyuk N.S. Cardiotoxicity and methods of its diagnosis in hematology patients (review). The Siberian Scientific Medical Journal. 2019;39(1):34-42 (in Russ.). DOI: 10.15372/SSMJ20190105. EDN: YZAKFN.Posch F., Niedrist T., Glantschnig T., Firla S., Moik F., Kolesnik E., Wallner M., Verheyen N., et al. Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc Med. 2022;9:933428. DOI: 10.3389/fcvm.2022.933428.Posch F., Niedrist T., Glantschnig T., Firla S., Moik F., Kolesnik E., Wallner M., Verheyen N., et al. Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc Med. 2022;9:933428. DOI: 10.3389/fcvm.2022.933428.Čelutkienė J., Plymen C.M., Flachskampf F.A., de Boer R.A., Grapsa J., Manka R., Anderson L., Garbi M., et al. Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(12):1615-1633. DOI: 10.1002/ejhf.1330.Čelutkienė J., Plymen C.M., Flachskampf F.A., de Boer R.A., Grapsa J., Manka R., Anderson L., Garbi M., et al. Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(12):1615-1633. DOI: 10.1002/ejhf.1330.Awadalla M., Hassan M.Z.O., Alvi R.M., Neilan T.G. Advanced imaging modalities to detect cardiotoxicity. Curr Probl Cancer. 2018;42(4):386-396. DOI: 10.1016/j.currproblcancer.2018.05.005.Awadalla M., Hassan M.Z.O., Alvi R.M., Neilan T.G. Advanced imaging modalities to detect cardiotoxicity. Curr Probl Cancer. 2018;42(4):386-396. DOI: 10.1016/j.currproblcancer.2018.05.005.Di Lisi D., Manno G., Novo G. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques. Curr Probl Cardiol. 2021;46(6):100818. DOI: 10.1016/j.cpcardiol.2021.100818.Di Lisi D., Manno G., Novo G. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques. Curr Probl Cardiol. 2021;46(6):100818. DOI: 10.1016/j.cpcardiol.2021.100818.Thavendiranathan P., Grant A.D., Negishi T., Plana J.C., Popovic Z.B., Marwick T.H. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77-84. DOI: 10.1016/j.jacc.2012.09.035.Thavendiranathan P., Grant A.D., Negishi T., Plana J.C., Popovic Z.B., Marwick T.H. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77-84. DOI: 10.1016/j.jacc.2012.09.035.Toro-Salazar O.H., Ferranti J., Lorenzoni R., Walling S., Mazur W., Raman S.V., Davey B.T., Gillan E., et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2016;29(2):119-131. DOI: 10.1016/j.echo.2015.10.008.Toro-Salazar O.H., Ferranti J., Lorenzoni R., Walling S., Mazur W., Raman S.V., Davey B.T., Gillan E., et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2016;29(2):119-131. DOI: 10.1016/j.echo.2015.10.008.Саидова М.А., Авалян А.А., Ощепкова Е.В., Шитов В.Н., Чазова И.Е. Сравнительные возможности метода спекл-трекинг-эхокардиографии в двумерном и трехмерном режимах в выявлении субклинической кардиотоксичности у больных раком молочной железы. Терапевтический архив. 2020;92(12):142-147. DOI: 10.26442/00403660.2020.12.200431. EDN: XGQQKU.Saidova M.A., Avalyan A.A., Oshchepkova E.V., Shitov V.N., Chazova I.E.Comparative capabilities of the speckle-tracking echocardiography technologiesin two-dimensional and three-dimensional modes in the detection of subclinical cardiotoxicity in patients with breast cancer. Terapevticheskii arkhiv. 2020;92(12):142-147 (in Russ.). DOI: 10.26442/00403660.2020.12.200431. EDN: XGQQKU.Corrigendum to ‘Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)’ [Eur J Heart Fail 2020;22:1504-1524]. Eur J Heart Fail. 2021;23(2):345. DOI: 10.1002/ejhf.2153.Corrigendum to ‘Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)’ [Eur J Heart Fail 2020;22:1504-1524]. Eur J Heart Fail. 2021;23(2):345. DOI: 10.1002/ejhf.2153.Никифоров В.С., Никищенкова Ю.В. Cовременные возможности speckle tracking эхокардиографии в клинической практике. Рациональная Фармакотерапия в Кардиологии. 2017;13(2):248-255. DOI: 10.20996/1819-6446-2017-13-2-248-255. EDN: YOCTIR.Nikiforov V.S., Nikishchenkova I.V. Modern Possibilities of Speckle Tracking Echocardiography in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2017;13(2):248-255 (in Russ.). DOI: 10.20996/1819-6446-2017-13-2-248-255. EDN: YOCTIR.Baron T., Berglund L., Hedin E.M., Flachskampf F.A. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. DOI: 10.1007/s00392-018-1363-7.Baron T., Berglund L., Hedin E.M., Flachskampf F.A. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. DOI: 10.1007/s00392-018-1363-7.Alam S., Chandra S., Saran M., Chaudhary G., Sharma A., Bhandhari M., Vishwakarma P., Pradhan A., et al. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Indian Heart J. 2019;71(6):468-475. DOI: 10.1016/j.ihj.2019.11.253.Alam S., Chandra S., Saran M., Chaudhary G., Sharma A., Bhandhari M., Vishwakarma P., Pradhan A., et al. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Indian Heart J. 2019;71(6):468-475. DOI: 10.1016/j.ihj.2019.11.253.Авалян А.А., Саидова М.А., Ощепкова Е.В., Чазова И.Е. Современные подходы к выявлению ранней субклинической кардиотоксичности, индуцированной химиотерапией, у больных раком молочной железы. Евразийский Кардиологический Журнал. 2018;(3):50-61. EDN: XYZPKX.Avalyan A.A., Saidova M.A., Oshchepkova E.V., Chazova I.Y. Modern approaches to detecting early subclinical cardiotoxicity induced by chemotherapy in patients with breast cancer. Eurasian heart journal. 2018;(3):50-61 (in Russ.). EDN: XYZPKX.Gripp E.A., Oliveira G.E., Feijó L.A., Garcia M.I., Xavier S.S., Sousa A.S. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. Arq Bras Cardiol. 2018;110(2):140-150. DOI: 10.5935/abc.20180021.Gripp E.A., Oliveira G.E., Feijó L.A., Garcia M.I., Xavier S.S., Sousa A.S. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. Arq Bras Cardiol. 2018;110(2):140-150. DOI: 10.5935/abc.20180021.Guerra F., Marchesini M., Contadini D., Menditto A., Morelli M., Piccolo E., Battelli N., Pistelli M., et al. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Support Care Cancer. 2016;24(7):3139-3145. DOI: 10.1007/s00520-016-3137-y.Guerra F., Marchesini M., Contadini D., Menditto A., Morelli M., Piccolo E., Battelli N., Pistelli M., et al. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Support Care Cancer. 2016;24(7):3139-3145. DOI: 10.1007/s00520-016-3137-y.Paraskevaidis I.A., Makavos G., Tsirigotis P., Psarogiannakopoulos P., Parissis J., Gkirkas K., Pessach I., Ikonomidis I. Deformation analysis of myocardial layers detects early cardiac dysfunction after chemotherapy in bone marrow transplantation patients: a continuous and additive cardiotoxicity process. J Am Soc Echocardiogr. 2017;30(11):1091-1102. DOI: 10.1016/j.echo.2017.07.010.Paraskevaidis I.A., Makavos G., Tsirigotis P., Psarogiannakopoulos P., Parissis J., Gkirkas K., Pessach I., Ikonomidis I. Deformation analysis of myocardial layers detects early cardiac dysfunction after chemotherapy in bone marrow transplantation patients: a continuous and additive cardiotoxicity process. J Am Soc Echocardiogr. 2017;30(11):1091-1102. DOI: 10.1016/j.echo.2017.07.010.Oikonomou E.K., Kokkinidis D.G., Kampaktsis P.N., Amir E.A., Marwick T.H., Gupta D., Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019;4(10):1007-1018. DOI: 10.1001/jamacardio.2019.2952.Oikonomou E.K., Kokkinidis D.G., Kampaktsis P.N., Amir E.A., Marwick T.H., Gupta D., Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiol. 2019;4(10):1007-1018. DOI: 10.1001/jamacardio.2019.2952.Ali M.T., Yucel E., Bouras S., Wang L., Fei H.W., Halpern E.F., Scherrer-Crosbie M. Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. J Am Soc Echocardiogr. 2016;29(6):522-527.e3. DOI: 10.1016/j.echo.2016.02.018.Ali M.T., Yucel E., Bouras S., Wang L., Fei H.W., Halpern E.F., Scherrer-Crosbie M. Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. J Am Soc Echocardiogr. 2016;29(6):522-527.e3. DOI: 10.1016/j.echo.2016.02.018.Milks M.W., Velez M.R., Mehta N., Ishola A., Van Houten T., Yildiz V.O., Reinbolt R., Lustberg M., et al. Usefulness of integrating heart failure risk factors into impairment of global longitudinal strain to predict anthracycline-related cardiac dysfunction. Am J Cardiol. 2018;121(7):867-873. DOI: 10.1016/j.amjcard.2017.12.022.Milks M.W., Velez M.R., Mehta N., Ishola A., Van Houten T., Yildiz V.O., Reinbolt R., Lustberg M., et al. Usefulness of integrating heart failure risk factors into impairment of global longitudinal strain to predict anthracycline-related cardiac dysfunction. Am J Cardiol. 2018;121(7):867-873. DOI: 10.1016/j.amjcard.2017.12.022.Liu J.E., Barac A., Thavendiranathan P., Scherrer-Crosbie M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020;2(5):677-689. DOI: 10.1016/j.jaccao.2020.10.011.Liu J.E., Barac A., Thavendiranathan P., Scherrer-Crosbie M. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020;2(5):677-689. DOI: 10.1016/j.jaccao.2020.10.011.Fei H.W., Ali M.T., Tan T.C., Cheng K.H., Salama L., Hua L., Zeng X., Halpern E.F., et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography. 2016;33(4): 519-526. DOI: 10.1111/echo.13168.Fei H.W., Ali M.T., Tan T.C., Cheng K.H., Salama L., Hua L., Zeng X., Halpern E.F., et al. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. Echocardiography. 2016;33(4): 519-526. DOI: 10.1111/echo.13168.Tadic M., Baudisch A., Haßfeld S., Heinzel F., Cuspidi C., Burkhardt F., Escher F., Attanasio P., et al. Right ventricular function and mechanics in chemotherapy- and radiotherapy-naïve cancer patients.Int J Cardiovasc Imaging. 2018;34(10):1581-1587. DOI: 10.1007/s10554-018-1379-0.Tadic M., Baudisch A., Haßfeld S., Heinzel F., Cuspidi C., Burkhardt F., Escher F., Attanasio P., et al. Right ventricular function and mechanics in chemotherapy- and radiotherapy-naïve cancer patients.Int J Cardiovasc Imaging. 2018;34(10):1581-1587. DOI: 10.1007/s10554-018-1379-0.Chang W.T., Shih J.Y., Feng Y.H., Chiang C.Y., Kuo Y.H., Chen W.Y., Wu H.C., Cheng J.T., et al. The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer. Acta Cardiol Sin. 2016;32(5):550-559. DOI: 10.6515/acs20151023a.Chang W.T., Shih J.Y., Feng Y.H., Chiang C.Y., Kuo Y.H., Chen W.Y., Wu H.C., Cheng J.T., et al. The early predictive value of right ventricular strain in epirubicin-induced cardiotoxicity in patients with breast cancer. Acta Cardiol Sin. 2016;32(5):550-559. DOI: 10.6515/acs20151023a.Florescu M., Magda L.S., Enescu O.A., Jinga D., Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83-92. DOI: 10.1016/j.echo.2013.10.008.Florescu M., Magda L.S., Enescu O.A., Jinga D., Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83-92. DOI: 10.1016/j.echo.2013.10.008.Thavendiranathan P., Negishi T., Somerset E., Negishi K., Penicka M., Lemieux J., Aakhus S., Miyazaki S., et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021;77(4):392-401. DOI: 10.1016/j.jacc.2020.11.020.Thavendiranathan P., Negishi T., Somerset E., Negishi K., Penicka M., Lemieux J., Aakhus S., Miyazaki S., et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021;77(4):392-401. DOI: 10.1016/j.jacc.2020.11.020.Negishi T., Thavendiranathan P., Penicka M., Lemieux J., Murbraech K., Miyazaki S., Shirazi M., Santoro C., et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269-278. DOI: 10.1016/j.jcmg.2022.10.010.Negishi T., Thavendiranathan P., Penicka M., Lemieux J., Murbraech K., Miyazaki S., Shirazi M., Santoro C., et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269-278. DOI: 10.1016/j.jcmg.2022.10.010.Papadopoulos K., Özden Tok Ö., Mitrousi K., Ikonomidis I. Myocardial Work: Methodology and Clinical Applications. Diagnostics (Basel). 2021;11(3):573. DOI: 10.3390/diagnostics11030573.Papadopoulos K., Özden Tok Ö., Mitrousi K., Ikonomidis I. Myocardial Work: Methodology and Clinical Applications. Diagnostics (Basel). 2021;11(3):573. DOI: 10.3390/diagnostics11030573.Boe E., Russell K., Eek C., Eriksen M., Remme E.W., Smiseth O.A., Skulstad H. Non-invasive myocardial work index identifies acute coronary occlusion in patients with non-ST-segment elevation-acute coronary syndrome. Eur Heart J Cardiovasc Imaging. 2015;16(11):1247-1255. DOI: 10.1093/ehjci/jev078.Boe E., Russell K., Eek C., Eriksen M., Remme E.W., Smiseth O.A., Skulstad H. Non-invasive myocardial work index identifies acute coronary occlusion in patients with non-ST-segment elevation-acute coronary syndrome. Eur Heart J Cardiovasc Imaging. 2015;16(11):1247-1255. DOI: 10.1093/ehjci/jev078.Kosmala W., Negishi T., Thavendiranathan P., Penicka M., De Blois J., Murbræch K., Miyazaki S., Shirazi M., et al. Incremental Value of Myocardial Work over Global Longitudinal Strain in the Surveillance for Cancer-Treatment-Related Cardiac Dysfunction: A Case-Control Study. J Clin Med. 2022;11(4):912. DOI: 10.3390/jcm11040912.Kosmala W., Negishi T., Thavendiranathan P., Penicka M., De Blois J., Murbræch K., Miyazaki S., Shirazi M., et al. Incremental Value of Myocardial Work over Global Longitudinal Strain in the Surveillance for Cancer-Treatment-Related Cardiac Dysfunction: A Case-Control Study. J Clin Med. 2022;11(4):912. DOI: 10.3390/jcm11040912.Zhang L., Zhang R., Shuai P., Chen J., Yin L. A global case meta-analysis of three-dimensional speckle tracking for evaluating the cardiotoxicity of anthracycline chemotherapy in breast cancer. Front Cardiovasc Med. 2022;9:942620. DOI: 10.3389/fcvm.2022.942620.Zhang L., Zhang R., Shuai P., Chen J., Yin L. A global case meta-analysis of three-dimensional speckle tracking for evaluating the cardiotoxicity of anthracycline chemotherapy in breast cancer. Front Cardiovasc Med. 2022;9:942620. DOI: 10.3389/fcvm.2022.942620.Zhai Z., Qin W., Wang Z., Dong S., Guo X., Zhang C., Wang Z., Lu G., Huang L. Changes in left ventricular function induced by carboplatin combined with paclitaxel in patients with ovarian cancer identified using three-dimensional spot tracking imaging technology. J Clin Ultrasound. 2021;49(4):378-384. DOI: 10.1002/jcu.22941.Zhai Z., Qin W., Wang Z., Dong S., Guo X., Zhang C., Wang Z., Lu G., Huang L. Changes in left ventricular function induced by carboplatin combined with paclitaxel in patients with ovarian cancer identified using three-dimensional spot tracking imaging technology. J Clin Ultrasound. 2021;49(4):378-384. DOI: 10.1002/jcu.22941.Wang Z., Qin W., Zhai Z., Huang L., Feng J., Guo X., Liu K., Zhang C., et al. Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.Int J Cardiovasc Imaging. 2021;37(4):1203-1213. DOI: 10.1007/s10554-020-02103-0.Wang Z., Qin W., Zhai Z., Huang L., Feng J., Guo X., Liu K., Zhang C., et al. Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.Int J Cardiovasc Imaging. 2021;37(4):1203-1213. DOI: 10.1007/s10554-020-02103-0.Alam S., Chandra S., Saran M., Chaudhary G., Sharma A., Bhandhari M., Vishwakarma P., Pradhan A., et al. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Indian Heart J. 2019;71(6):468-475. DOI: 10.1016/j.ihj.2019.11.253.Alam S., Chandra S., Saran M., Chaudhary G., Sharma A., Bhandhari M., Vishwakarma P., Pradhan A., et al. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy. Indian Heart J. 2019;71(6):468-475. DOI: 10.1016/j.ihj.2019.11.253.Coutinho Cruz M., Moura Branco L., Portugal G., Galrinho A., Timóteo A.T., Rio P., Ilhão Moreira R., Mendonça T., et al. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines. Clin Res Cardiol. 2020;109(6):673-684. DOI: 10.1007/s00392-019-01556-1.Coutinho Cruz M., Moura Branco L., Portugal G., Galrinho A., Timóteo A.T., Rio P., Ilhão Moreira R., Mendonça T., et al. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines. Clin Res Cardiol. 2020;109(6):673-684. DOI: 10.1007/s00392-019-01556-1.Song F., Kang Y., Zhang C., Xu Y., Shi J., Guo Y., Zhang Q., Shu X., et al. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography. Cardiol J. 2017;24(5):484-494. DOI: 10.5603/CJ.a2017.0035.Song F., Kang Y., Zhang C., Xu Y., Shi J., Guo Y., Zhang Q., Shu X., et al. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography. Cardiol J. 2017;24(5):484-494. DOI: 10.5603/CJ.a2017.0035.Jeong D., Gladish G., Chitiboi T., Fradley M.G., Gage K.L., Schiebler M.L. MRI in cardio-oncology: A review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019;50(5):1349-1366. DOI: 10.1002/jmri.26895.Jeong D., Gladish G., Chitiboi T., Fradley M.G., Gage K.L., Schiebler M.L. MRI in cardio-oncology: A review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019;50(5):1349-1366. DOI: 10.1002/jmri.26895.Saunderson C.E.D., Plein S., Manisty C.H. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021;22(4):383-396. DOI: 10.1093/ehjci/jeaa345.Saunderson C.E.D., Plein S., Manisty C.H. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021;22(4):383-396. DOI: 10.1093/ehjci/jeaa345.Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., Zlotoff D.A., Murphy S.P., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733-1743. DOI: 10.1093/eurheartj/ehaa051.Zhang L., Awadalla M., Mahmood S.S., Nohria A., Hassan M.Z.O., Thuny F., Zlotoff D.A., Murphy S.P., et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733-1743. DOI: 10.1093/eurheartj/ehaa051.Faron A., Isaak A., Mesropyan N., Reinert M., Schwab K., Sirokay J., Sprinkart A.M., Bauernfeind F.G., et al. Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. Radiology. 2021;301(3):602-609. DOI: 10.1148/radiol.2021210814.Faron A., Isaak A., Mesropyan N., Reinert M., Schwab K., Sirokay J., Sprinkart A.M., Bauernfeind F.G., et al. Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. Radiology. 2021;301(3):602-609. DOI: 10.1148/radiol.2021210814.Liu J., Cao Y., Zhu K., Yao S., Yuan M., Kong X., Liu X., Li Y., et al. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study. Quant Imaging Med Surg. 2022;12(10): 4771-4785. DOI: 10.21037/qims-22-41.Liu J., Cao Y., Zhu K., Yao S., Yuan M., Kong X., Liu X., Li Y., et al. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study. Quant Imaging Med Surg. 2022;12(10): 4771-4785. DOI: 10.21037/qims-22-41.Lambert J., Lamacie M., Thampinathan B., Altaha M.A., Esmaeilzadeh M., Nolan M., Fresno C.U., Somerset E., et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817-823. DOI: 10.1136/heartjnl-2019-316297.Lambert J., Lamacie M., Thampinathan B., Altaha M.A., Esmaeilzadeh M., Nolan M., Fresno C.U., Somerset E., et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817-823. DOI: 10.1136/heartjnl-2019-316297.Houbois C.P., Nolan M., Somerset E., Shalmon T., Esmaeilzadeh M., Lamacie M.M., Amir E., Brezden-Masley C., et al. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC Cardiovasc Imaging. 2021;14(5): 962-974. DOI: 10.1016/j.jcmg.2020.09.039Houbois C.P., Nolan M., Somerset E., Shalmon T., Esmaeilzadeh M., Lamacie M.M., Amir E., Brezden-Masley C., et al. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC Cardiovasc Imaging. 2021;14(5): 962-974. DOI: 10.1016/j.jcmg.2020.09.039Minotti G., Menna P., Camilli M., Salvatorelli E., Reggiardo G. Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal. J Pharmacol Exp Ther. 2021;376(2):231-239. DOI: 10.1124/jpet.120.000323.Minotti G., Menna P., Camilli M., Salvatorelli E., Reggiardo G. Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal. J Pharmacol Exp Ther. 2021;376(2):231-239. DOI: 10.1124/jpet.120.000323.Upshaw J.N., Finkelman B., Hubbard R.A., Smith A.M., Narayan H.K., Arndt L., Domchek S., DeMichele A., et al.Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):198-210. DOI: 10.1016/j.jcmg.2019.07.018.Upshaw J.N., Finkelman B., Hubbard R.A., Smith A.M., Narayan H.K., Arndt L., Domchek S., DeMichele A., et al.Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):198-210. DOI: 10.1016/j.jcmg.2019.07.018.Lange S.A., Jung J., Jaeck A., Hitschold T., Ebner B. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients. Cardiovasc Toxicol. 2016;16(2): 193-206. DOI: 10.1007/s12012-015-9328-9.Lange S.A., Jung J., Jaeck A., Hitschold T., Ebner B. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients. Cardiovasc Toxicol. 2016;16(2): 193-206. DOI: 10.1007/s12012-015-9328-9.

The authors declare that there are no conflicts of interest present.